TNFSF11 and Duchenne muscular dystrophy: Interestingly, an exploratory post hoc analysis we performed reveals that treatment with denosumab, a human monoclonal antibody targeting RANKL, appears to have reduced cardiac hypertrophy in two children with DMD.